The PennZone

TEMPE, Ariz. - PennZone -- GT Medical Technologies, Inc. today announced its GammaTile^® Surgically Targeted Radiation Therapy (STaRT) for patients with brain tumors will be spotlighted at the 2021 CNS Annual Meeting exhibition October 18-20 in Austin, Texas, and at the 15^th Tumor Section Satellite Symposium which immediately precedes it October 15-16.

"Neurological surgeons and affiliated healthcare professionals attend these prestigious events to learn about the latest advancements in neurosurgical care," said Matthew E. Likens, president and CEO of GT Medical Technologies, Inc. "We look forward to sharing our valuable data that demonstrates how GammaTile Therapy has significantly improved traditional brain tumor radiation and patient outcomes."

More on The PennZone

• Holiday Gambling Spending Expected to Rise 12% in December
• RAS AP Consulting Issues National Compliance Alert and Launches Q4 2026 AP Readiness Program Ahead of IRS FIRE → IRIS Cutover
• Free Senior Housing Webinar Helps Families Plan for Aging Before a Crisis Forces Difficult Decisions
• Claude Zdanow named Managing Director in Miami, Florida
• YWCA Hanover Celebrates Opening of New Children's Learning Academy

Tumor Section Satellite Symposium
This two-day Symposium features engaging scientific sessions that explore technological advances in neurosurgical neuro-oncology. Attendees will have the opportunity to learn more about GammaTile Therapy in a Lunch Symposium on Saturday, October 16 at 12:15 p.m.

• Focus: Neurosurgical Oncology
• October 15-16 | JW Marriott, Austin Texas
• GT Medical Technologies booth 200
• Saturday, October 16, 12:15 PM-1:15 PM: GammaTile^® Therapy: Technology and Device Overview

CNS Annual Meeting
Once a year, thousands of neurosurgeons, physicians, and affiliates from around the globe come together to attend the CNS Annual Meeting to hear about the latest technological improvements in neurosurgical treatment. This will be the first in-person conference since 2019, due to the necessity of a virtual exchange in 2020. This year, attendees can visit GT Medical Technologies at booth 1750 to learn more about GammaTile Therapy.

• October 18-20 Exhibits | Austin Convention Center
• GT Medical Technologies booth 1750

About GT Medical Technologies, Inc.

More on The PennZone

• Pregis Launches Sharp InfinX: On-Demand Rightsized Mailing System Delivering a Precision-Sized Mailer for Every Order
• netElastic Announces vBNG And CGNAT 2.0 General Availability
• Postmortem Pathology Highlights Private Autopsy Options for Las Vegas Families During Summer Months
• Postmortem Pathology Offers Sacramento Families Independent Answers on a Short Timeline
• Philly ECM Programming Announces Mobile Module Programming for Philadelphia Repair Shops

Driven to overcome the limitations of current treatments for brain tumors and raise the standard of care, a team of brain tumor specialists joined forces and formed GT Medical Technologies with the purpose of improving the lives of patients with brain tumors. Its GammaTile Therapy received FDA 510(k) regulatory clearance for the treatment of all types of recurrent brain tumors and newly diagnosed malignant tumors. Patients receive their course of radiation while going about their daily lives, requiring no additional trips to the hospital or clinic for radiation therapy. GammaTile is available in top brain tumor centers across the United States. For more information or to find a GammaTile center near you, visit https://www.gtmedtech.com/ and follow @GTMedTech on Twitter and LinkedIn.